<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29136562</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>07</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>12</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-2472</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>160</Volume>
            <PubDate>
              <Year>2017</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Thrombosis research</Title>
          <ISOAbbreviation>Thromb Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis.</ArticleTitle>
        <Pagination>
          <StartPage>97</StartPage>
          <EndPage>104</EndPage>
          <MedlinePgn>97-104</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.thromres.2017.11.001</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0049-3848(17)30544-3</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study aims to assess the effect of warfarin resumption in patients who experienced warfarin-associated intracranial hemorrhage (ICH).</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a systematic review and meta-analysis of studies evaluating the outcomes of adult patients who survived warfarin-associated ICH. We included studies that compared patients who resumed warfarin versus those who did not.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 3145 studies screened, ten observational studies were included in the final analysis. Death occurred in 181 of 968 patients (18.7%) who resumed warfarin and 834 of 2579 (32.3%) who did not resume warfarin (RR 0.51, 95% CI 0.34 to 0.76, P=0.0009). Ischemic stroke occurred in 32 of 902 (3.5%) patients who resumed warfarin and 172 of 2467 (7.0%) patients who did not resume warfarin (RR 0.56, 95% CI 0.39 to 0.82, P=0.002). Venous thromboembolism occurred in 4 of 224 (1.8%) patients who resumed warfarin and of 33 of 681 (4.8%) patients who did not resume warfarin (RR 0.39, 95% CI, 0.15 to 1.03, P=0.06). Recurrent ICH occurred in 200 of 2994 (6.7%) patients who resumed warfarin and 358 of 4652 (7.7%) patients who did not resume warfarin (RR 0.89, 95% CI 0.65 to 1.23, P=0.49).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The study suggests that warfarin resumption is associated with significant reduction in ischemic stroke and venous thromboembolism when compared to no warfarin resumption in patients who experience warfarin-associated ICH. Although these results are strongly supportive of restarting anticoagulation, prospective studies are required to confirm our results due to the high likelihood of bias in the included studies.</AbstractText>
          <CopyrightInformation>Copyright Â© 2017 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chai-Adisaksopha</LastName>
            <ForeName>Chatree</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, McMaster University, Hamilton, Canada; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iorio</LastName>
            <ForeName>Alfonso</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, McMaster University, Hamilton, Canada; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hillis</LastName>
            <ForeName>Christopher</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, McMaster University, Hamilton, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Siegal</LastName>
            <ForeName>Deborah</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, McMaster University, Hamilton, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Witt</LastName>
            <ForeName>Daniel M</ForeName>
            <Initials>DM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacotherapy, The University of Utah, Salt Lake City, UT, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schulman</LastName>
            <ForeName>Sam</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, McMaster University, Hamilton, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Crowther</LastName>
            <ForeName>Mark</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, McMaster University, Hamilton, Canada; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada. Electronic address: crowthrm@mcmaster.ca.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Thromb Res</MedlineTA>
        <NlmUniqueID>0326377</NlmUniqueID>
        <ISSNLinking>0049-3848</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>5Q7ZVV76EI</RegistryNumber>
          <NameOfSubstance UI="D014859">Warfarin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020300" MajorTopicYN="N">Intracranial Hemorrhages</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014859" MajorTopicYN="N">Warfarin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>9</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29136562</ArticleId>
        <ArticleId IdType="doi">10.1016/j.thromres.2017.11.001</ArticleId>
        <ArticleId IdType="pii">S0049-3848(17)30544-3</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
